#USA #New York #Securities Class Action #Faruqi & Faruqi #Capricor Therapeutics

Capricor Investors Face Important Legal Deadline

Faruqi & Faruqi, LLP, a distinguished national law firm specializing in securities litigation, has announced a critical notice for investors in Capricor Therapeutics, Inc. This advisory highlights the impending deadline of September 28, 2026, for shareholders who suffered losses to consider participating in a federal securities class action lawsuit against the company.

This investigation revolves around alleged violations of federal securities laws by Capricor and its executives. Investors who purchased shares between December 17, 2025, and July 26, 2026, could be eligible to act as lead plaintiffs in this ongoing litigation. Faruqi & Faruqi's Senior Partner, James (Josh) Wilson, encourages affected investors to inquire directly about their options and rights.

Allegations Against Capricor

According to the lawsuit, significant accusations have surfaced against Capricor concerning its clinical treatment, Deramiocel. The allegations assert that the company made misleading claims and omitted crucial information regarding changes to a pre-specified statistical analysis plan essential for analyzing clinical data for Deramiocel. Specifically, it is contended that Capricor failed to secure the FDA's approval for these changes before resubmitting the Biologics License Application (BLA).

These undisclosed alterations reportedly contributed to a heightened risk that the FDA would find insufficient evidence regarding Deramiocel's effectiveness. Consequently, this situation greatly endangered its chances for regulatory approval intended for treating Duchenne muscular dystrophy.

The repercussions became evident shortly after the FDA revealed briefing documents stating a 'unfavorable benefit-risk assessment’ for Deramiocel due to the lack of effectiveness evidence. Following this disclosure on July 27, 2026, Capricor's stock plummeted a staggering 64%, closing at $7.00. Another blow came on July 30, 2026, when the FDA's Advisory Committee, in a 9-3 non-binding vote, indicated that evidence did not support Deramiocel's efficacy for treating DMD-associated cardiomyopathy, leading to an additional 36% fall in the stock price, closing at $4.19.

Legal Rights and Participation

The class action lawsuit emphasizes that any members of the class can advocate to serve as lead plaintiffs—a role that entails representing the interests of all investors seeking damages. This action can be initiated through legal counsel of their choosing or, alternatively, shareholders can choose to remain absent from the proceedings.

Faruqi & Faruqi also invites individuals with relevant information about Capricor's conduct, including whistleblowers, former employees, and shareholders, to come forward to aid in building a stronger case.

It is crucial for investors who acquired stocks during the relevant timeframe to review their transaction records and prepare necessary documentation that can substantiate their claims. All necessary communication and records should be preserved to enhance their standing in potential recovery.

Why Choose Faruqi & Faruqi?

Faruqi & Faruqi has a proven track record in representing investors, having successfully recovered hundreds of millions of dollars since its establishment in 1995. For investors interested in exploring their legal rights regarding this case, the firm offers consultations free of charge. Potential claimants are urged to reach out prior to the September deadline to assess their eligibility for participation in this securities class action. Interested parties should consult with the firm to better understand their legal stance and the proceedings ahead, including the implications of becoming a lead plaintiff.

For further information about the Capricor class action, individuals can contact Josh Wilson at 877-247-4292 or 212-983-9330 Ext. 1310 or visit Faruqi & Faruqi's website.

Conclusion

As the deadline approaches, it is imperative for affected investors to act swiftly. With significant legal implications at stake, engaging with a reputable securities law firm like Faruqi & Faruqi can provide vital guidance and ensure that their voices are heard within the legal proceedings surrounding Capricor Therapeutics. The data indicates that timely action may provide the route not only for justice but also for potential financial recovery.